Sequenom's Q2 Revenues Sink 28 Percent on Softness in Capital Equipment Market | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom reported after the market closed Thursday that its second-quarter revenues declined 28 percent, which it said was primarily due to softness in the capital equipment market.

The San Diego-based firm generated total revenues of $9.2 million for the three-month period ended June 30, down from $12.8 million for the second quarter of 2008. The company beat analysts' consensus revenue estimate of $8.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.